慢性便秘に対するエロビキシバットの長期使用

基本情報

NCT ID

NCT04784780

ステータス

不明

試験のフェーズ

第4相

試験タイプ

介入

目標被験者数

100

治験依頼者名

Yokohama City University

概要

In this double-blind comparative study, AJG533 (elobixibat) 10 mg or AJG533 placebo was orally administered once daily before meals for 12 weeks in patients with chronic constipation, and the primary endpoint was the change from Week 2 of the observation period in the number of complete spontaneous bowel movements (CSBM) at Week 12 of the treatment period. The primary endpoint was the change in the number of complete spontaneous bowel movements (CSBM) from Week 2 of the observation period.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)